We are analyzing https://link.springer.com/article/10.1007/s11523-017-0484-7.

Title:
Sorafenib: A Review in Hepatocellular Carcinoma | Targeted Oncology
Description:
Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with advanced HCC, which showed significantly longer median overall survival (OS) and time to radiological progression (TTP) with sorafenib 400 mg twice daily than with placebo, with no significant between-group difference in the median time to symptomatic progression (TTSP). Subsequent results from real-world studies such as GIDEON also support the use of sorafenib in HCC, including in carefully selected CP class B patients, although the median OS achieved in these patients appears relatively short. Sorafenib has a well characterized tolerability and safety profile, with strategies available to prevent and manage adverse effects such as hand-foot skin reactions. In conclusion, sorafenib remains an important option for the treatment of HCC.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

sorafenib, article, pubmed, google, scholar, hepatocellular, carcinoma, cas, patients, advanced, study, oncol, cancer, phase, clin, gideon, trial, analysis, treatment, clinical, hcc, safety, liver, iii, hepatol, randomized, central, abstract, results, access, practice, chen, suppl, efficacy, kudo, content, therapeutic, tumor, res, cheng, privacy, cookies, function, information, search, oncology, review, keating, unresectable, therapy,

Topics {✒️}

targets raf/mek/erk pathway month download article/chapter /html/products/pi/nexavar_pi raf/mek/erk pathway abou-alfa gk hand-foot skin reactions tyrosine kinases vegfr/pdgfr open-label study major kinase-independent target ketoconazole-mediated cyp3a inhibition sorafenib relieves cell-intrinsic pro-apoptotic sorafenib signaling di costanzo related subjects llovet jm full article pdf open-label privacy choices/manage cookies augment antitumor immunity asia-pacific region phase iii study dual-action inhibitor intermediate stage hcc phase iii trial field-practice study phase iii failure liver function assessment cheng a cell-extrinsic inhibitions phase ii study sorafenib asia-pacific randomized clinical trial cell death dis european economic area international observational study patient surveillance study phase iv study murine hepatocytes depends european patient subset advanced hepatocellular carcinoma phase iii randomised randomized controlled trial sunitinib versus sorafenib brivanib versus sorafenib linifanib versus sorafenib doxorubicin versus sorafenib advanced hepatocellular cancer systemic agent approved manage adverse effects bayer healthcare pharmaceuticals

Questions {❓}

Learning from 7 years of experience with sorafenib in advanced HCC: sorafenib better than sorafenib?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Sorafenib: A Review in Hepatocellular Carcinoma
         description:Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with advanced HCC, which showed significantly longer median overall survival (OS) and time to radiological progression (TTP) with sorafenib 400 mg twice daily than with placebo, with no significant between-group difference in the median time to symptomatic progression (TTSP). Subsequent results from real-world studies such as GIDEON also support the use of sorafenib in HCC, including in carefully selected CP class B patients, although the median OS achieved in these patients appears relatively short. Sorafenib has a well characterized tolerability and safety profile, with strategies available to prevent and manage adverse effects such as hand-foot skin reactions. In conclusion, sorafenib remains an important option for the treatment of HCC.
         datePublished:2017-03-15T00:00:00Z
         dateModified:2017-03-15T00:00:00Z
         pageStart:243
         pageEnd:253
         sameAs:https://doi.org/10.1007/s11523-017-0484-7
         keywords:
            Overall Survival
            Sorafenib
            Tace
            Median Overall Survival
            National Comprehensive Cancer Network
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0484-7/MediaObjects/11523_2017_484_Figa_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0484-7/MediaObjects/11523_2017_484_Figb_HTML.gif
         isPartOf:
            name:Targeted Oncology
            issn:
               1776-260X
               1776-2596
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Gillian M. Keating
               affiliation:
                     name:Springer
                     address:
                        name:Springer, Auckland, New Zealand
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Sorafenib: A Review in Hepatocellular Carcinoma
      description:Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with advanced HCC, which showed significantly longer median overall survival (OS) and time to radiological progression (TTP) with sorafenib 400 mg twice daily than with placebo, with no significant between-group difference in the median time to symptomatic progression (TTSP). Subsequent results from real-world studies such as GIDEON also support the use of sorafenib in HCC, including in carefully selected CP class B patients, although the median OS achieved in these patients appears relatively short. Sorafenib has a well characterized tolerability and safety profile, with strategies available to prevent and manage adverse effects such as hand-foot skin reactions. In conclusion, sorafenib remains an important option for the treatment of HCC.
      datePublished:2017-03-15T00:00:00Z
      dateModified:2017-03-15T00:00:00Z
      pageStart:243
      pageEnd:253
      sameAs:https://doi.org/10.1007/s11523-017-0484-7
      keywords:
         Overall Survival
         Sorafenib
         Tace
         Median Overall Survival
         National Comprehensive Cancer Network
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0484-7/MediaObjects/11523_2017_484_Figa_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0484-7/MediaObjects/11523_2017_484_Figb_HTML.gif
      isPartOf:
         name:Targeted Oncology
         issn:
            1776-260X
            1776-2596
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Gillian M. Keating
            affiliation:
                  name:Springer
                  address:
                     name:Springer, Auckland, New Zealand
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Targeted Oncology
      issn:
         1776-260X
         1776-2596
      volumeNumber:12
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Springer
      address:
         name:Springer, Auckland, New Zealand
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Gillian M. Keating
      affiliation:
            name:Springer
            address:
               name:Springer, Auckland, New Zealand
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Springer, Auckland, New Zealand
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(206)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

3.89s.

LINK . SPRINGER . COM {}